ADVERTISEMENT

Type 2 diabetes: cardiovascular and renal benefits of empagliflozin vs dapagliflozin

Miriam Tucker   |   Clinical Summary   |   26 October 2022
ADVERTISEMENT

Takeaway

  • Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use was associated with a significantly reduced risk for atherosclerotic cardiovascular disease (ASCVD), hospitalisation for heart failure (HHF), and renal events compared with dipeptidyl peptidase-4 inhibitors (DPP4is) among patients with type 2 diabetes without baseline ASCVD, HF, or chronic kidney disease.
  • No significant differences were...

          

Topic Challenges

left
right